ئۆکسیندۆلۆن: جیاوازیی نێوان پێداچوونەوەکان

'''ئۆکسیندۆلۆن،''' بەتەنھا و لەژێر ناوی بازرگانی پرۆستێتین و ڕاکسەنۆن دەفرۆشرێ، دەرمانێکی [[دژە ئەندرۆجین|دژە ئەندرۆجینە]] و [[پڕۆجێستۆجین (دەرمان)|پرۆجستینە]] کە لە [[ژاپۆن]] بۆ چارەسەری گەورە بوونی [[پرۆستات]] بەکاردێت<ref name="Elks2014">{{cite book|author=J. Elks|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA914|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=914–}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935-IA129|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref><ref name="NegwerScharnow2001">{{cite book|author1=Martin Negwer|url=https://books.google.com/books?id=zmpqAAAAMAAJ|title=Organic-chemical drugs and their synonyms: (an international survey)|author2=Hans-Georg Scharnow|publisher=Wiley-VCH|year=2001|isbn=978-3-527-30247-5|page=2023}}</ref><ref name="TanLi2014">{{cite journal|last1=Tan|first1=MH Eileen|last2=Li|first2=Jun|last3=Xu|first3=H Eric|last4=Melcher|first4=Karsten|last5=Yong|first5=Eu-leong|year=2014|title=Androgen receptor: structure, role in prostate cancer and drug discovery|journal=Acta Pharmacologica Sinica|volume=36|issue=1|pages=3–23|doi=10.1038/aps.2014.18|issn=1671-4083|pmc=4571323|pmid=24909511}}</ref><ref name="IshizukaNishizawa2002">{{cite journal|last1=Ishizuka|first1=Osamu|last2=Nishizawa|first2=Osamu|last3=Hirao|first3=Yoshihiko|last4=Ohshima|first4=Shinichi|year=2002|title=Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy|journal=International Journal of Urology|volume=9|issue=11|pages=607–612|doi=10.1046/j.1442-2042.2002.00539.x|issn=0919-8172|pmid=12534901}}</ref>ھەرچۆنێک بێت بەکارھێنانەکەی پەسەند نەکراوە بەھۆی کاریگەرییە ھەستیارییەکانی<ref name="IshizukaNishizawa20022">{{cite journal|last1=Ishizuka|first1=Osamu|last2=Nishizawa|first2=Osamu|last3=Hirao|first3=Yoshihiko|last4=Ohshima|first4=Shinichi|year=2002|title=Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy|journal=International Journal of Urology|volume=9|issue=11|pages=607–612|doi=10.1046/j.1442-2042.2002.00539.x|issn=0919-8172|pmid=12534901}}</ref> ئۆکسیندۆلۆن کاریگەر نییە لە [[دەرمان لە ڕێگەی دەم|ڕێگەی دەمەوە]]، پێویستە لە ڕێگەی دەرزی لە [[ماسوولکە|ماسولکە]] بدرێت<ref name="RathboneHadgraft2002">{{cite book|author1=Michael J. Rathbone|url=https://books.google.com/books?id=mw9W82MLYZ8C&pg=PA368|title=Modified-Release Drug Delivery Technology|author2=Jonathan Hadgraft|author3=Michael S. Roberts|date=7 November 2002|publisher=CRC Press|isbn=978-0-8247-0869-6|pages=368–}}</ref><ref name="pmid6131442">{{cite journal|vauthors=Henkler G, Klotzbach M, Koch H, Müller W, Richter J|year=1982|title=[Progress in the area of drug development. 15]|journal=Pharmazie|language=de|volume=37|issue=11|pages=753–65|pmid=6131442|quote=[Oxendolone] has been clinically tested in Japan (weekly intramuscular injection of 200-400 mg) in prostatic hypertrophy.}}</ref><ref name="pmid26335395">{{cite journal|vauthors=Hikichi Y, Yamaoka M, Kusaka M, Hara T|year=2015|title=Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile|journal=Eur. J. Pharmacol.|volume=765|pages=322–31|doi=10.1016/j.ejphar.2015.08.052|pmid=26335395|quote=According to the clinical data of TSAA-291, the plasma level of TSAA-291 after weekly intramuscular administration at 400 mg/kg for 12 weeks is approximately 100 nM (Drug Information).}}</ref><ref name="pmid2466359">{{cite journal|vauthors=Ostri P, Swartz R, Meyhoff HH, Petersen JH, Lindgård G, Frimodt-Møller C, Andersson T, Nielsen MS|year=1989|title=Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial|journal=Urol. Res.|volume=17|issue=1|pages=29–33|doi=10.1007/bf00261046|pmid=2466359|quote=Thirty patients were treated with weekly injections of oxendolone 200 mg during a 3 months' period, and 30 patients were allocated to placebo treatment.}}</ref><ref name="pmid6419414">{{cite journal|vauthors=Midgley I, Fowkes AG, Darragh A, Lambe R, Chasseaud LF, Taylor T|year=1983|title=The metabolic fate of the anti-androgenic agent, oxendolone, in man|url=https://archive.org/details/sim_steroids_1983-04_41_4/page/521|journal=Steroids|volume=41|issue=4|pages=521–36|doi=10.1016/0039-128x(83)90092-2|pmid=6419414|quote=After intramuscular administration of 16β-ethyl-17β-hydroxy-4-[4-14C] estren-3-one (14C-oxendolone; 300 mg) to 3 human subjects, [...]}}</ref>